A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.
Quincy S. Chu
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Randeep S. Sangha
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sebastien J Hotte
No relevant relationships to disclose
Gwen Sergenson
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Roxana Sufan
Employment or Leadership Position - Boehringer Ingelheim
Yu Gu
Employment or Leadership Position - Boehringer Ingelheim
David Schnell
Employment or Leadership Position - Boehringer Ingelheim
Hal W. Hirte
No relevant relationships to disclose